108 related articles for article (PubMed ID: 7911694)
1. Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line.
Melguizo C; Prados J; Fernández JE; Vélez C; Alvarez L; Aránega A
Cell Mol Biol (Noisy-le-grand); 1994 Mar; 40(2):137-45. PubMed ID: 7911694
[TBL] [Abstract][Full Text] [Related]
2. Differentiation of a human rhabdomyosarcoma cell line after antineoplastic drug treatment.
Melguizo C; Prados J; Aneiros J; Fernandez JE; Velez C; Aranega A
J Pathol; 1995 Jan; 175(1):23-9. PubMed ID: 7891223
[TBL] [Abstract][Full Text] [Related]
3. Inverse expression of mdr 1 and c-myc genes in a rhabdomyosarcoma cell line resistant to actinomycin d.
Prados J; Melguizo C; Fernández A; Aránega AE; Alvarez L; Aránega A
J Pathol; 1996 Sep; 180(1):85-9. PubMed ID: 8943821
[TBL] [Abstract][Full Text] [Related]
4. Stable differentiation of a human colon adenocarcinoma cell line by sodium butyrate is associated with multidrug resistance.
Ho SB; Yan PS; Dahiya R; Neuschwander-Tetri BA; Basbaum C; Kim YS
J Cell Physiol; 1994 Aug; 160(2):213-26. PubMed ID: 7913708
[TBL] [Abstract][Full Text] [Related]
5. Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD.
Melguizo C; Prados J; Marchal JA; Aránega AE; Alvarez L; Aránega A
Pathol Res Pract; 1996 Feb; 192(2):188-94. PubMed ID: 8692721
[TBL] [Abstract][Full Text] [Related]
6. Modulation of HLA class I expression in multidrug-resistant human rhabdomyosarcoma cells.
Melguizo C; Prados J; Marchal JA; Vélez C; Carrillo E; Boulaiz H; Sánchez-Montesinos I; Madeddu R; Aránega A
Neoplasma; 2003; 50(2):91-6. PubMed ID: 12740641
[TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibodies recognizing a Mr 180,000 P-glycoprotein: differential expression of the Mr 180,000 and Mr 170,000 P-glycoproteins in multidrug-resistant human tumor cells.
Meyers MB; Rittmann-Grauer L; O'Brien JP; Safa AR
Cancer Res; 1989 Jun; 49(12):3209-14. PubMed ID: 2566379
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
9. Development of multidrug resistance in a primitive neuroectodermal tumor cell line.
Tishler DM; Raffel C
J Neurosurg; 1992 Mar; 76(3):502-6. PubMed ID: 1346631
[TBL] [Abstract][Full Text] [Related]
10. Potentiation of vincristine and actinomycin D by a new synthetic imidazole anti-tumor agent YM534 active against human cancer cells and multidrug-resistant cells.
Sato S; Watanabe Y; Okamura K; Hamanaka R; Mori T; Kohno K; Kuwano M
Anticancer Drug Des; 1989 Aug; 4(2):125-35. PubMed ID: 2803461
[TBL] [Abstract][Full Text] [Related]
11. GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells.
Marchal JA; Prados J; Melguizo C; Gómez JA; Campos J; Gallo MA; Espinosa A; Arena N; Aránega A
Br J Cancer; 1999 Feb; 79(5-6):807-13. PubMed ID: 10070873
[TBL] [Abstract][Full Text] [Related]
12. Study of multi-drug resistant mechanisms in a taxol-resistant hepatocellular carcinoma QGY-TR 50 cell line.
Zhou J; Cheng SC; Luo D; Xie Y
Biochem Biophys Res Commun; 2001 Feb; 280(5):1237-42. PubMed ID: 11162660
[TBL] [Abstract][Full Text] [Related]
13. Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein.
Lindman H; Taube A; Bergh JC
Anticancer Res; 1994; 14(2A):363-6. PubMed ID: 7912491
[TBL] [Abstract][Full Text] [Related]
14. Establishment of doxorubicin-resistant human bladder cancer cell line (BUI-87/ADMR) and its mechanism of multidrug resistance.
Guo H; Lu G; Xiong X; Dong J; Liu S
Chin Med J (Engl); 1997 Mar; 110(3):167-72. PubMed ID: 9594332
[TBL] [Abstract][Full Text] [Related]
15. Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells.
Papahadjopoulos D; Poste G; Vail WJ; Biedler JL
Cancer Res; 1976 Sep; 36(9 pt.1):2988-94. PubMed ID: 975068
[TBL] [Abstract][Full Text] [Related]
16. Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice.
Mattern J; Bak M; Volm M
Anticancer Res; 1990; 10(1):177-80. PubMed ID: 1970715
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein expression in ovarian cancer cell line following treatment with cisplatin.
Yang X; Pagé M
Oncol Res; 1995; 7(12):619-24. PubMed ID: 8704279
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen aziridine, a novel affinity probe for P-glycoprotein in multidrug resistant cells.
Safa AR; Roberts S; Agresti M; Fine RL
Biochem Biophys Res Commun; 1994 Jul; 202(1):606-12. PubMed ID: 7913604
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins.
Volm M; Bak M; Mattern J
Arzneimittelforschung; 1988 Aug; 38(8):1189-93. PubMed ID: 3196414
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic differentiation in a human rhabdomyosarcoma cell line selected for resistance to actinomycin D.
Prados J; Melguizo C; Marchal JA; Vélez C; Alvarez L; Aránega A
Int J Cancer; 1998 Jan; 75(3):379-83. PubMed ID: 9455797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
